Allena Pharmaceuticals, Inc. (ALNA) Social Stream

Featured Post From StockTwits About ALNA

$ALNA I am bullish on this:
-Cash is reasonable now. With 52M at July 2021. Risk of re-dilution is quite low in 2021.
-No competitors and no options currently for Enteric Hyperoxaluria which has a significant morbidity, mortality and cost burden = high market penetration expected.
-Learning from all previous studies, the Co. de-risked the URIROX-2 protocol = the chances are higher than average for success: such as overpowering with up to 200 pts, taking sicker patients, extending the results to 16-24 weeks, lowering to 2 TABs from 3-5x daily, etc.
-The new data from phase 1a/1b in ALLN-346 is all positive and they are smoothly cruising so far through phase 2a.
-Patents are strong and know how of production complex.
Catalysts:
*ALLN-346. Phase 2a interim results in Q4 2021.
*Urirox 2. Interim analysis in Q1 2022, BLA submission in Q4 2022.